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y 6, 2013.his study sought to characterize the prevalence of metabolic syndrome (MetS), its 5 components, and
their pharmacological treatment in U.S. adults by sex and race/ethnicity over time.Background MetS is a constellation of clinical risk factors for cardiovascular disease, stroke, kidney disease, and
type 2 diabetes mellitus.Methods Prevalence estimates were estimated in adults (20 years of age) from the National Health and Nutrition
Examination Survey (NHANES) from 1999 to 2010 (in 2-year survey waves). The biological thresholds, deﬁned by the
2009 Joint Scientiﬁc Statement, were: 1) waist circumference 102 cm (males adults) and 88 cm (female
adults); 2) fasting plasma glucose 100 mg/dl; 3) blood pressure ofS130/85 mm Hg; 4) triglycerides 150 mg/
dl; and 5) high-density lipoprotein-cholesterol (HDL-C) <40 mg/dl (male adults) and <50 mg/dl (female adults).
Prescription drug use was estimated for lipid-modifying agents, anti-hypertensives, and anti-hyperglycemic
medications.Results From 1999 and 2000 to 2009 and 2010, the age-adjusted prevalence of MetS (based on biologic thresholds)
decreased from 25.5% (95% conﬁdence interval [CI]: 22.5% to 28.6%) to 22.9% (95% CI: 20.3% to 25.5%). During
this period, hypertriglyceridemia prevalence decreased (33.5% to 24.3%), as did elevated blood pressure (32.3% to
24.0%). The prevalence of hyperglycemia increased (12.9% to 19.9%), as did elevated waist circumference (45.4%
to 56.1%). These trends varied considerably by sex and race/ethnicity. Decreases in elevated blood pressure,
suboptimal triglycerides, and high-density lipoprotein-cholesterol prevalence have corresponded with increases in
anti-hypertensive and lipid-modifying drugs, respectively.Conclusions The increasing prevalence of abdominal obesity, particularly among female adults, highlights the urgency of
addressing abdominal obesity as a healthcare priority. The use of therapies for MetS components aligns with
favorable trends in their prevalence. (J Am Coll Cardiol 2013;62:697–703) ª 2013 by the American College of
Cardiology FoundationIn this paper, we examine trends in the prevalence ofmetabolic
syndrome (MetS), its 5 components, and their pharmacolog-
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2012; revised manuscript received April 5, 2013,a constellation of clinical criteria, is used to identify patients at
increased risk for cardiovascular disease (CVD), type II dia-
betes mellitus (T2DM), and all-cause mortality (1–4). The
integrated epidemiological concept of MetS originated from
the observation that several metabolic risk factors often co-
occur in patients at high risk of CVD, namely abdominal
obesity, dyslipidemia, elevated bloodpressure, impaired fasting
glucose, and insulin resistance (5). The risk factors that
comprise MetS are independently associated with CVD and
T2DM and have become the therapeutic targets of lifestyle
modiﬁcation, medications, and surgical interventions (6).
Furthermore, there is evidence that MetS is an effective and
simple clinical tool for identifying high-risk subjects predis-
posed to CVD and T2DM (7). Although these targets
have been in place for more than a decade, U.S. trends of
MetS prevalence in the overall population and across sex
Table 1 Components of the Metabolic Syndrome
Components* Term Deﬁned Cutoff
Elevated waist
circumference
Abdominal
obesity
102 cm for male adults, and 88 cm
for female adults in the United
States (11)
Elevated blood
pressure
Hypertension Systolic BP 130 mm Hg, diastolic
BP 85 mm Hg or anti-hypertensive
drug treatment in a patient with
history of hypertension (3)
Elevated
triglycerides
Dyslipidemia Triglycerides 150 mg/dl or drug
treatment for elevated triglycerides
Low HDL-C Dyslipidemia HDL-C<40mg/dl inmen or<50mg/dl
in women or drug treatment for
reduced HDL-C (3)
Elevated fasting
plasma
glucose
Hyperglycemia 100 mg/dl or drug treatment for
elevated glucose (3)
Abbreviations
and Acronyms
CI = conﬁdence interval
CVD = cardiovascular
disease
HDL-C = high-density
lipoprotein cholesterol
MA = Mexican-American
MetS = metabolic syndrome
NHANES = National Health
and Nutrition Examination
Survey
T2DM = type II diabetes
mellitus
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698and race/ethnicity groups have not
been characterized. The primary
objectives of this paper are to: 1)
examine trends in the prevalence
of MetS, its components, and the
pharmacological treatments used
to control these components in the
adult U.S. population between
1999 and 2010; and 2) compare
time trends in these risk factors by
race/ethnicity and sex.
Methods
We used data from the National
*The presence of any 3 of 5 components results in a diagnosis of the metabolic syndrome. Source:
2009 Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology
and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart
Federation; International Atherosclerosis Society; and International Association for the Study of
Obesity (3).
BP ¼ blood pressure; HDL-C ¼ high-density lipoprotein cholesterol.Health and Nutrition Examination Survey (NHANES)
representative of the civilian, noninstitutionalized U.S.
population (8). The NHANES is a series of cross-sectional,
national, stratiﬁed, multistage probability surveys of the
civilian, noninstitutionalized U.S. population conducted by
the Centers for Disease Control and Prevention. Beginning
in 1999, NHANES became a continuous program with 2-
year cycles meant to provide national estimates of the U.S.
population. Participants were recruited using a multistage,
stratiﬁed sampling design consisting of 4 stages of selection:
1) counties or small groups of contiguous counties; 2) a block
or group of blocks containing a cluster of households;
3) households; and 4) 1 or more participants from house-
holds. Because of the differential probabilities of selection,
sampling weights were created to reﬂect the base proba-
bilities of selection, adjustment for nonresponse, and post-
stratiﬁcation. All adults provided written informed consent;
the study was approved by the National Center for Health
Statistics Institutional/Ethics Review Board. This analysis
was reviewed by the University of Pennsylvania Institutional
Review Board and was considered exempt from full review.
Our study data were collected in 6 of the 2-year cycles
from 1999 to 2000 and from 2009 to 2010. We included
individuals aged 20 or older who self-reported as Mexican-
American (MA), non-MAwhite (hereinafter white), or non-
MA black (hereinafter black) who fasted for 8 h or more and
had complete information on the relevant variables of interest
(e.g., glucose, HDL-C, triglycerides, blood pressure, and
waist circumference). We excluded individuals who did not
fulﬁll the fasting criteria and those whose fasting status was
unknown leading to a ﬁnal analytic sample with the following
individuals: 1,613 in 1999 to 2000; 1,908 in 2001 to 2002;
1,687 in 2003 to 2004; 1,703 in 2005 to 2006; 1,869 in 2007
to 2008; and 2,034 in 2009 to 2010 (Online Tables 1 and 2).
The Online Appendix describes the data, sample selection,
andmethods used to estimate all components of the syndrome
and other aspects of the analysis (see the expanded Methods
section in the Online Appendix).
Brieﬂy, MetS was estimated using criteria consistent with
the most recent harmonized deﬁnition of MetS published in
2009 (Table 1) (3,9). Patients who met 3 or more of thecriteria were deﬁned as having MetS. Waist circumference
was measured at the high point of the iliac crest at minimal
respiration to the nearest 0.1 cm. Serum triglyceride
concentrations were enzymatically measured after hydro-
lyzation to glycerol, and HDL-C was measured after the
precipitation of other lipoproteins with a heparin–manga-
nese chloride mixture. Plasma glucose concentrations were
determined using an enzymatic reaction. Up to 4 attempts
were made to collect 3 blood pressure readings in the mobile
examination center; the average of all available measures was
used. Race/ethnicity was determined by self-reported survey
responses, and categorized as non-MA white, non-MA
black, and MA.
To complement the trends analysis in the clinical (bio-
logical) thresholds of the MetS, we also estimated the age-
adjusted prevalence of the use of each of the following
prescription drug classes: 1) lipid-modifying agents; 2) anti-
hypertensive; and 3) anti-hyperglycemic medications.
Although the Joint Scientiﬁc Statement (3) classiﬁes use of
these agents as an equal criterion for meeting the deﬁnition
of speciﬁc components (e.g., using anti-hypertensive medi-
cation is equal to being hypertensive), medication use in
NHANES is coded based on the therapeutic indication of
the attendant generic drug code, thus the true indication is
unknown. Although NHANES collects information on
self-reported use of medication for high blood pressure and
glucose, such information is not available for lipid medica-
tion. As lipid-modifying agents (e.g., statins or ﬁbric acids
derivatives) can both increase HDL-C and lower triglyceride
levels (10,11), we chose to focus on trends in classes of drugs
rather than make assumptions on therapeutic indication that
might lead to overestimates of MetS. The interview weight
was used for trends in medications. A list of the medications
used and their therapeutic indicators are provided in the
Online Appendix.
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699We used age standardized prevalence estimates through the
direct method using the 2000 U.S. population as the standard
(see the expanded Methods section in the Online Appendix
for detailed summary of the statistical methods). This allows
examination of the prevalence of MetS and its components
over time. For time–trend analysis, our primary outcome was
the prevalence rate of change per year from survey wave 1
(1999 to 2000) to survey wave 6 (2009 to 2010). We used 2
modeling strategies, both age-adjusted, by ﬁtting separate
models for each sex and race/ethnicity group for MetS and
its individual components. First, we modeled the likelihood
that an individual had MetS or had met each of the MetS
components using logistic regression. Second, we estimated
MetS prevalence as the ratio of the number of cases in
comparison with the total population using a Poisson model.
All models were age-adjusted and the direction and signiﬁ-
cance level for both model speciﬁcations were qualitatively
equivalent. Statistical analyses accounted for the complex
sampling design, nonresponse, differential sampling, and
noncoverage, as recommended by the NHANES statistical
documentation. The NHANES morning fasting sample
weight was used for all MetS and its component-speciﬁc
prevalence estimates.
Results
Approximately one-ﬁfth of the adult U.S. population remains
at high cardiometabolic risk (Table 2). From 1999 to 2010,
the age-adjusted prevalence of MetS (based on biological
thresholds) decreased from 25.5% (95% CI: 22.5% to 28.6%)
to 22.9% (95% CI: 20.3% to 25.5%) (ptrend ¼ 0.024). The
MA race, particularly female adults, have a higher MetS
prevalence than the other subgroups.
Although the prevalence of MetS has declined in the total
population when measuring clinical targets, there is a diver-
gence in trends for its individual components, mainly in high
waist circumference for the total population and among the
sex and race/ethnicity groups (Fig. 1). For example, the
prevalence of abdominal obesity for the total population
increased from 45.4% (95% CI: 40.7% to 50.0%) in 1999 to
56.1% (CI: 52.8% to 59.4%) in 2010. Of note, baseline rates
of abdominal obesity were much higher among female adults
than male adults, particularly among MAs (Online Tables 4
to 6). Estimates of elevated blood pressure for the total
population declined over time from 32.3% (29.0% to 35.6%)
in 1999 to 24.0% (20.9% to 27.1%) (ptrend <0.001) in 2010
(Table 2). Among male adults, only whites experienced
a decline in elevated blood pressure, whereas among female
adults, both whites and MAs showed a decline. This
reduction aligns with increased awareness and pharmaco-
logical treatment of elevated blood pressure (Fig. 2). The
prevalence of hypertriglyceridemia also declined in the total
population over the study period, from 33.5% (29.8% to
37.3%) to 24.3% (21.6% to 26.9%) (ptrend <0.001). Similar
to elevated blood pressure, all racial groups experienced
a decline in elevated triglycerides except for blacks (OnlineTables 4 to 6), although the latter group showed the lowest
baseline prevalence of hypertriglyceridemia (Fig. 1). During
the same time period the use of lipid-modifying agents rose
from 8% (7.3% to 8.7%) to 15.6% (14.6% to 16.5%) in the
total NHANES sample (Fig. 2). A similar trend in greater
use of lipid-modifying agents was observed among all of the
population subgroups. Although some of the variability in
HDL-C trends between 2001 and 2006 is likely attributable
to a change in the laboratory assay during this time period
(12), there was an overall decline in suboptimal HDL-C in
the total population from 38.5% (33.6% to 43.5%) in 1999 to
30.1% (29.9% to 33.2%) in 2010 (ptrend <0.001). All racial
groups experienced a decline in the prevalence of suboptimal
HDL-C over time (Online Table 4), except for black males
(Online Table 5). In contrast to the reduced prevalence of
other MetS components, the prevalence of hyperglycemia
rose in the total population from 12.9% (95% CI: 9.8% to
16.0%) in 1999 to 19.9% (95% CI: 16.4% to 23.5%) in 2010
(ptrend <0.001) (Table 2), with the MA male adults group
having the fastest increase among all subgroups of the
population.
Comment
We found that the prevalence of MetS has slightly declined
when measured on the basis of clinical targets using the
biological thresholds outlined in Adult Treatment Panel-3
(10,11) and the Joint Scientiﬁc Statement (3). However,
even with this decline, approximately one-ﬁfth of the adult
U.S. population would be classiﬁed as having MetS, living
with suboptimal measures for at least 3 of 5 MetS compo-
nents. These results indicate a limited decline in the prev-
alence of MetS in the past decade. Our results are consistent
with an earlier analysis of NHANES III (1988 to 1994) that
used similar ATP III criteria to deﬁne MetS and found that
approximately 22% of U.S. adults (24% after age adjust-
ment) had MetS, with similar sex and race/ethnicity
patterning (13).
The MetS is an epidemiological construct of different
permutations of risk factors, each with unique clinical
implications and treatment strategies (14). Understanding
the trends in the population’s burden of MetS is valuable
given the recognition that certain cardiometabolic risk
factors tend to co-exist. There is evidence suggesting that
speciﬁc clusters of 3 or more MetS factors are not necessarily
associated with greater risk for CVD outcomes and that
fasting glucose is the main predictor of T2DM (15).
However, it is important to identify the population with
MetS because these individuals have a particularly adverse
metabolic state that warrants aggressive intervention for
speciﬁc traits. For example, results from the Framingham
Study indicate that trait combinations that did not include
fasting glucose also imparted an increased risk for incident
T2DM (15). Increasing awareness of MetS may also
account for some of the declines in its component risk
factors. For instance, in our analysis and in previous evidence
Table 2 Age-Standardized Prevalence of the Metabolic Syndrome in the United States, 1999 to 2010
Total Population 1999–2000 2001–2002 2003–2004 2005–2006 2007–2008 2009–2010 ptrend
Metabolic syndrome
Total population 25.54% (22.49–28.58) 27.37% (25.25–29.50) 25.76% (22.98–28.53) 23.18% (20.22–26.15) 24.94% (21.46–28.42) 22.90% (20.28–25.53) 0.024
Male adults 23.35% (18.04–28.65) 27.45% (23.96–30.94) 25.26% (20.50–30.02) 24.57% (20.78–28.35) 26.54% (23.57–29.50) 23.69% (18.79–28.58) 0.54
Female adults 27.50% (24.49–30.50) 26.98% (24.54–29.42) 26.20% (22.05–30.35) 22.10% (18.19–26.01) 23.54% (18.69–28.38) 21.80% (19.04–24.56) 0.005
Waist circumference
Total population 45.35% (40.66–50.04) 48.96% (46.18–51.74) 55.35% (52.29–58.41) 54.24% (50.64–57.84) 53.78% (50.60–56.95) 56.07% (52.79–59.35) <0.001
Male adults 36.48% (30.55–42.41) 39.82% (35.30–44.33) 46.02% (41.52–50.51) 46.41% (42.17–50.64) 45.44% (41.88–49.01) 46.44% (41.22–51.66) 0.011
Female adults 53.53% (48.55–58.51) 57.67% (53.59–61.75) 64.41% (60.03–68.79) 61.70% (56.80–66.60) 61.93% (56.82–67.04) 65.38% (62.36–68.39) <0.001
Blood pressure
Total population 32.30% (29.00–35.61) 34.69% (31.60–37.77) 30.56% (27.35–33.78) 30.44% (27.80–33.08) 24.25% (22.28–26.21) 24.04% (20.91–27.18) <0.001
Male adults 35.22% (30.66–39.78) 37.21% (31.93–42.50) 34.64% (29.74–39.54) 33.95% (30.75–37.16) 25.18% (22.21–28.15) 27.84% (23.99–31.69) <0.001
Female adults 29.28% (25.99–32.56) 32.15% (29.33–34.98) 26.42% (23.24–29.59) 27.27% (23.39–31.15) 22.80% (20.15–25.45) 20.19% (17.02–23.36) <0.001
Triglycerides
Total population 33.53% (29.76–37.30) 33.32% (31.22–35.41) 32.37% (28.97–35.77) 30.20% (26.84–33.56) 28.84% (26.12–31.56) 24.25% (21.57–26.93) <0.001
Male adults 35.04% (28.17–41.91) 37.85% (33.50–42.21) 36.06% (31.01–41.10) 35.45% (31.24–39.67) 34.71% (30.88–38.55) 26.26% (21.89–30.62) 0.004
Female adults 32.03% (28.17–35.90) 28.54% (26.78–30.30) 28.50% (24.74–32.25) 25.24% (21.83–28.66) 23.56% (19.84–27.28) 21.74% (17.76–25.71) <0.001
HDL-C
Total population 38.51% (33.56–43.46) 33.86% (31.13–36.59) 27.50% (24.60–30.39) 21.33% (19.05–23.62) 28.30% (24.21–32.40) 30.05% (26.93–33.16) <0.001
Male adults 35.56% (29.59–41.53) 31.57% (27.72–35.43) 22.49% (16.86–28.12) 20.61% (17.52–23.70) 27.28% (23.72–30.85) 27.91% (23.81–32.01) 0.004
Female adults 41.04% (35.14–46.93) 35.97% (32.99–38.96) 32.48% (27.09–37.87) 22.16% (18.89–25.43) 29.30% (23.83–34.78) 32.00% (28.69–35.30) <0.001
Glucose
Total population 12.94% (9.84–16.04) 15.62% (13.58–17.66) 14.15% (12.53–15.76) 17.89% (15.34–20.44) 22.82% (19.71–25.94) 19.92% (16.38–23.47) <0.001
Male adults 16.44% (12.17–20.70) 18.77% (15.26–22.27) 17.76% (15.22–20.30) 20.54% (16.45–24.62) 28.64% (24.31–32.97) 25.01% (20.10–29.92) <0.001
Female adults 10.05% (7.85–12.25) 12.58% (11.12–14.05) 10.41% (8.17–12.66) 15.60% (12.45–18.75) 17.46% (13.51–21.40) 15.14% (11.98–18.30) <0.001
Values are % (95% conﬁdence interval).
HDL-C ¼ high-density lipoprotein cholesterol.
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Figure 1 Prevalence and Trends of the 5 Components of Metabolic Syndrome in the Adult U.S. Population, 1999 to 2010
Prevalence and trends of the components of MetS for U.S. adults age 20 years or older for the total population by sex (ﬁrst column), by race/ethnicity (second column), and by
race/ethnicity and sex (third and fourth columns). Waist circumf. ¼ waist circumference; HDL-C ¼ high-density lipoprotein cholesterol; Non-Mex-Am ¼ non-Mexican American.
Table 1 shows the cut-offs deﬁned as high risk for each indicator. Shaded areas represent 95% conﬁdence intervals.
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701of time trends in MetS components, there has been a decline
in average lipid levels among U.S. adults from 1960 to 2006,
which has largely been attributed to the growing proportion
of the population receiving lipid-lowering medication
(16,17). Perhaps the successes we have observed in lipid
management are partly due to increasing clinical recognition
of the importance of screening for this variable in the
presence of abdominal obesity (e.g., as both are components
of MetS). In the current analysis, MetS components had
divergent trends. We observed pronounced declines in
dyslipidemia, speciﬁcally in hypertriglyceridemia, results that
align with previous studies (18). Concurrent with improve-
ments in dyslipidemia, we observed higher use of drugs over
time that target suboptimal lipid proﬁles such as statins,
ﬁbrates, and niacin derivatives (Fig. 2). Indeed, favorable
trends in blood pressure and dyslipidemia may reﬂect
increasing availability and use of pharmacologicalinterventions. This is in contrast to our observations on the
increasing trend of abdominal obesity, most pronounced in
female adults, which may identify a population at a poten-
tially high cardiometabolic risk. Particularly important are
the sex and racial differences in the prevalence of increased
waist circumference. White male adults are more likely to
have abdominal obesity than their counterparts of other race/
ethnicity, but the opposite is true among white female
adults.
Also notable are the sex and racial differences in
the prevalence of individual MetS components. We found
that white male adults are more likely to have abdominal
obesity than their counterparts of other race/ethnicity, but
the opposite is true among white female adults. We also
found that black male adults and black female adults
consistently had a higher prevalence of elevated blood
pressure than other groups, but they showed the lowest
Figure 2
Prevalence and Trends of Prescription Drug Use Related to Components of Metabolic Syndrome in the
Adult U.S. Population, 1999 to 2010
Prescription drug use related to components of MetS for U.S. adults age 20 years or older for the total population by sex (ﬁrst column), by race/ethnicity (second column), and
by race/ethnicity and sex (third and fourth columns). Online Table 7 shows the speciﬁc medications included as anti-hypertensive, lipid-modifying agents, and anti-
hyperglycemic. Shaded areas represent 95% conﬁdence intervals. Abbreviations as in Figure 1.
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702dyslipidemia prevalence levels. Additionally, MAs, both
overall and by sex, consistently had a higher prevalence of
low HDL-C, high triglycerides, and high blood glucose
than other subgroups.
Study limitations. It is likely that multitudes of factors, in
addition to known risk factors, affect cardiometabolic risk.
These may include socioeconomic status and regional
differences in access to care, which we did not measure in
our analysis. Also, trends in HDL-C may be underestimated
due to variations in the assay during the study period (12).
NHANES provides adjusted estimates for effected survey
waves that exceed the maximum allowable bias, but these
changes are known to be responsible for secondary variation
in point estimates across the 6 waves (12). A more detailed
examination of these changes and their impact on the
measurement of HDL-C has been previously published
(16,17). In addition, conclusions that are based on strictcutoffs limit our understanding of individuals who are near
the cutoff points and may have risks similar to subjects with
MetS, but do not classify as meeting a certain risk factor
(19,20). The cutpoints for elevated waist circumference are
not well-deﬁned, particularly for subjects of non-European
race. It remains unclear whether the same criteria for
abdominal obesity should be applied to individuals of
a particular ethnic group, regardless of their country of
residence or origin (3). The most recent harmonized deﬁ-
nition of MetS has consistent cutoffs for all risk factors, but
recommends that the cutoff values for abdominal obesity be
selected based on the study or population being examined
(3). In the current analyses, we imposed the U.S. cutoffs (11)
on all NHANES respondents, consistent with the methods
of previous studies (13). Given that the U.S. cutoffs are the
most generous for deﬁning abdominal obesity (102 cm for
male adults and 88 cm for female adults), as compared
JACC Vol. 62, No. 8, 2013 Beltrán-Sánchez et al.
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703with potentially choosing the lower Latin American or
African cutoffs based on ancestry for racial subgroups, our
estimates of the burden of abdominal obesity may, in fact, be
conservative. Also, as the use of self-reported race/ethnicity
is susceptible to misclassiﬁcation bias, the NHANES
sampling strategy might be responsible for ﬂuctuations and
variation between the prevalence estimates in survey waves.
A ﬁnal limitation of this work is that while it demonstrates
MetS trends, it does not show how these trends correlate
with trends in clinically signiﬁcant outcomes, such as
cardiovascular morbidity and mortality. However, our
observation of divergent trends in MetS components is
important evidence of the ongoing burdens of risk for CVD
in the U.S., and suggests that priority should be placed in
addressing those risk factors that have increased in preva-
lence over the past decade (i.e., obesity and hyperglycemia)
(4,5,9,10).
Conclusions
Our analysis examined the patterns of MetS across 6 waves
of NHANES between 1999 and 2010 and showed that
although the prevalence of MetS (as it is currently deﬁned)
has declined slightly over time, there have been population-
level changes in its components. Most striking is the upward
trend in abdominal obesity across the entire U.S. population
since the ﬁrst survey wave in 1999 and 2000. Insulin resis-
tance also appears to be on the rise. However, there is
a downward trend in elevated triglycerides with a current
overall prevalence near 25% likely corresponding with
increased use of statins and other lipid-modifying agents.
Our results demonstrate potential targets for interventions to
reduce the future burden of CVD and T2DM, and conﬁrm
the urgent need for multifaceted and coordinated treatment
programs to address the increasing prevalence of obesity in
the United States.
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